BioAtla, Inc.
BCAB
$0.87
$0.045.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 1,582.36% | -95.41% | |||
| Gross Profit | -1,582.36% | 95.41% | |||
| SG&A Expenses | -14.37% | -5.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.05% | 5.86% | |||
| Operating Income | 26.05% | -5.86% | |||
| Income Before Tax | 15.68% | -22.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.68% | -22.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.68% | -22.02% | |||
| EBIT | 26.05% | -5.86% | |||
| EBITDA | 25.90% | -6.32% | |||
| EPS Basic | 16.01% | -21.50% | |||
| Normalized Basic EPS | 16.01% | -21.52% | |||
| EPS Diluted | 16.01% | -21.50% | |||
| Normalized Diluted EPS | 16.01% | -21.52% | |||
| Average Basic Shares Outstanding | 0.41% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.41% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||